CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Tecentriq & Avastin for Hepatocellular Carcinoma - Details

Project Number pCODR 10217
Brand Name Tecentriq & Avastin
Generic Name Atezolizumab & Bevacizumab
Strength 1200 mg/20 mL and 840 mg/14 mL
Tumour Type Gastrointestinal
Indication Hepatocellular Carcinoma (HCC)
Funding Request TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy. Maintenance TECENTRIQ should continue until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should continue until loss of clinical benefit or unacceptable toxicity.
Review Status Open for Feedback on Recommendation
Pre Noc Submission Yes
NOC Date August 7, 2020
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date May 21, 2020
Submission Deemed Complete June 4, 2020
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ June 4, 2020
Check-point meeting August 6, 2020
pERC Meeting October 15, 2020
Initial Recommendation Issued October 29, 2020
Feedback Deadline ‡ November 12, 2020
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.